Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Management of Irish ALK+ NSCLC patients with brigatinib

Jarushka Naidoo • 4 Nov 2020
Lung Cancer Non-Small Cell Lung Cancer Brigatinib Crizotinib
ALTA-1L

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, discusses the impact of the changes of brigatinib reimbursement in Irish patients with ALK+ non-small cell cancer (NSCLC), based on the results of the Phase III ALTA-1L study (NCT02737501). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

More from Jarushka Naidoo

1:11
Unanswered questions regarding the use of IO in NSCLC
Jarushka Naidoo • 5 Jun 2022
1:28
Highlights in NSCLC from ASCO 2022
Jarushka Naidoo • 5 Jun 2022
0:48
Chemotherapy-free immunotherapy-based treatment approaches for NSCLC
Jarushka Naidoo • 5 Jun 2022
1:44
Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLC
Jarushka Naidoo • 5 Jun 2022

Related Videos

0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals